Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B

The New England Journal of Medicine
Ching-Lung LaiBEHoLD AI463027 Study Group

Abstract

Entecavir is a potent and selective antiviral agent that has demonstrated efficacy in phase 2 studies in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. In this phase 3, double-blind trial, we randomly assigned 648 patients with HBeAg-negative chronic hepatitis B who had not previously been treated with a nucleoside analogue to receive 0.5 mg of entecavir or 100 mg of lamivudine once daily for a minimum of 52 weeks. The primary efficacy end point was histologic improvement (a decrease by at least two points in the Knodell necroinflammatory score, without worsening of fibrosis). Histologic improvement after 48 weeks of treatment occurred in 208 of 296 patients in the entecavir group who had adequate baseline liver-biopsy specimens that could be evaluated (70 percent), as compared with 174 of 287 such patients in the lamivudine group (61 percent, P=0.01). More patients in the entecavir group than in the lamivudine group had undetectable serum hepatitis B virus (HBV) DNA levels according to a polymerase-chain-reaction assay (90 percent vs. 72 percent, P<0.001) and normalization of alanine aminotransferase levels (78 percent vs. 71 percent, P=0.045). The mean reduction in serum HBV DNA levels from baseline...Continue Reading

References

Sep 1, 1981·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·R G KnodellJ Wollman
Jul 1, 1997·Antimicrobial Agents and Chemotherapy·S F InnaimoR J Colonno
Mar 3, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·N C TassopoulosD F Gray
Mar 8, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·H L ChanA S Lok
May 29, 2001·Gastroenterology·A S LokJ H Hoofnagle
Oct 5, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·S J Hadziyannis, D Vassilopoulos
Jun 27, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·George V PapatheodoridisStephanos J Hadziyannis
Feb 20, 2003·Journal of Hepatology·Hari S Conjeevaram, Anna Suk-Fong Lok
Feb 28, 2003·The New England Journal of Medicine·Stephanos J HadziyannisUNKNOWN Adefovir Dipivoxil 438 Study Group
Mar 5, 2003·Seminars in Liver Disease·Stephanos J HadziyannisDimitrios Vassilopoulos
Jul 24, 2003·Klinicheskaia meditsina·M M IbragimovaI V Popova
Dec 23, 2003·Alimentary Pharmacology & Therapeutics·G V Papatheodoridis, S J Hadziyannis
Jan 8, 2004·Journal of Hepatology·Giovanna Fattovich
Mar 5, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Anna S F LokUNKNOWN Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD)
Mar 16, 2004·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Emmet B KeeffeTeresa L Wright
Sep 17, 2004·The New England Journal of Medicine·Patrick MarcellinUNKNOWN Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group
Oct 8, 2004·The New England Journal of Medicine·Yun-Fan LiawUNKNOWN Cirrhosis Asian Lamivudine Multicentre Study Group
Jan 25, 2005·Journal of Hepatology·Mario RizzettoStephen D Gardner
Mar 10, 2006·The New England Journal of Medicine·Ting-Tsung ChangUNKNOWN BEHoLD AI463022 Study Group

❮ Previous
Next ❯

Citations

Aug 31, 2012·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Jessica P HwangRohit Loomba
May 29, 2007·Journal of Gastroenterology·Hiroshi Yotsuyanagi, Kazuhiko Koike
Jul 21, 2012·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Mehlika ToyCihan Yurdaydin
Jun 19, 2013·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Ming-Fa ChenJun Wu
Jan 5, 2011·Journal of General Internal Medicine·Tatyana A ShamliyanTimothy J Wilt
Mar 6, 2007·Current Gastroenterology Reports·Robert G Gish
May 31, 2008·Current HIV/AIDS Reports·Vincent SorianoPablo Barreiro
Aug 25, 2009·Current Infectious Disease Reports·Melissa Osborn
Jan 29, 2008·Current Treatment Options in Gastroenterology·Chee-Kin Hui, George K Lau
Aug 12, 2009·Hepatology International·Yock Young DanSeng Gee Lim
Jun 1, 2008·Hepatology International·Shiv Kumar Sarin, Manoj Kumar
Aug 12, 2009·Hepatology International·Yun-Fan LiawUNKNOWN Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver
Aug 12, 2009·Hepatology International·Ching-Lung Lai, Man-Fung Yuen
Jun 21, 2011·Hepatology International·Wai-Kay SetoChing-Lung Lai
Jun 1, 2011·Indian Journal of Virology : an Official Organ of Indian Virological Society·Ajay KumarRenu Pandey
Mar 27, 2013·Paediatric Drugs·Mona Abdel-Hady, Deirdre Kelly
Oct 6, 2010·Cellular & Molecular Immunology·Yanfang JiangJunqi Niu
Jun 3, 2008·Therapeutics and Clinical Risk Management·Evangelini DimouStephanos J Hadziyannis
Aug 3, 2006·Nature Clinical Practice. Gastroenterology & Hepatology·Smruti R MohantyVijay Khiani
Aug 3, 2006·Nature Clinical Practice. Gastroenterology & Hepatology·Frank Tacke, Christian Trautwein
Apr 26, 2007·Nature Reviews. Drug Discovery·Jules DienstagPeter Kirkpatrick
Mar 23, 2011·Nature Reviews. Gastroenterology & Hepatology·Hellan Kwon, Anna S Lok
Jul 21, 2006·The New England Journal of Medicine·Ting-Tsung Chang, Ching-Lung Lai
Mar 10, 2006·The New England Journal of Medicine·Jay H Hoofnagle
Dec 21, 2007·The New England Journal of Medicine·Ching-Lung LaiUNKNOWN Globe Study Group
Jan 28, 2011·The New England Journal of Medicine·Heiner WedemeyerUNKNOWN HIDIT Study Group
Oct 4, 2008·The New England Journal of Medicine·Jules L Dienstag
Oct 23, 2008·The Journal of Biological Chemistry·Egor P TchesnokovMatthias Götte
Oct 6, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Wang-Huei ShengShan-Chwen Chang
Oct 20, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Debika Bhattacharya, Chloe L Thio
Aug 13, 2009·The Journal of Antimicrobial Chemotherapy·C Y William TongTerry Wong
Nov 11, 2009·The Journal of Antimicrobial Chemotherapy·K LacombeP M Girard
Oct 4, 2011·The Journal of Antimicrobial Chemotherapy·James FungMan-Fung Yuen
Apr 7, 2007·Journal of Clinical Gastroenterology·Rekha Cheruvattath, Vijayan Balan
Mar 22, 2008·American Journal of Therapeutics·Emilio Palumbo
Apr 7, 2007·Current Opinion in Gastroenterology·Jessica Tan, Anna Sf Lok

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Related Papers

The New England Journal of Medicine
Ting-Tsung ChangBEHoLD AI463022 Study Group
The New England Journal of Medicine
S J HadziyannisAdefovir Dipivoxil 438 Study Group
The New England Journal of Medicine
Ching-Lung LaiGlobe Study Group
The New England Journal of Medicine
Patrick MarcellinPeginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group
© 2021 Meta ULC. All rights reserved